DiaMedica CEO granted 380,000 stock options

DiaMedica Therapeutics Inc. President & CEO Dietrich John Pauls received a grant of stock options covering 380,000 Voting Common Shares.

Rhea-AI Filing Summary

DiaMedica Therapeutics Inc. President & CEO Dietrich John Pauls received a grant of stock options covering 380,000 Voting Common Shares. The options have an exercise price of $5.84 per share and expire on June 1, 2036.

The award is compensation-related rather than an open-market trade. It is scheduled to vest 25% on the one-year anniversary of the grant date, with the remaining options vesting in twelve equal quarterly installments. Following this grant, he holds 380,000 stock options directly.

Insider Trade Summary

Grant/Award: 380,000 shares

Grant/Award 1 txn

Insider Pauls Dietrich John

Role President & CEO

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	380,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 380,000 contracts (Direct)

Footnotes (1)

1. F1. Scheduled to vest with respect to 25% of the shares on the one-year anniversary of the grant date, with the remaining shares scheduled to vest in twelve equivalent quarterly installments.

Key Figures

Option grant size: 380,000 options Exercise price: $5.84 per share Expiration date: June 1, 2036 +2 more

5 metrics

Option grant size 380,000 options Stock Option (right to buy) granted to President & CEO

Exercise price $5.84 per share Conversion or exercise price of stock options

Expiration date June 1, 2036 Option expiration for CEO grant

Underlying shares 380,000 Voting Common Shares Shares underlying the derivative security

Post-grant option holdings 380,000 options Total shares following transaction, direct ownership

Key Terms

Stock Option (right to buy), Grant, award, or other acquisition, Voting Common Shares, vest

4 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

Voting Common Shares financial

"underlying_security_title: Voting Common Shares"

vest financial

"Scheduled to vest with respect to 25% of the shares"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did DiaMedica Therapeutics (DMAC) disclose in this Form 4?

The filing shows President & CEO Dietrich John Pauls received a grant of 380,000 stock options. These options are a compensation award, not an open-market trade, and relate to DiaMedica Therapeutics’ Voting Common Shares.

How many stock options did the DiaMedica (DMAC) CEO receive?

Dietrich John Pauls was granted 380,000 stock options tied to DiaMedica’s Voting Common Shares. This award brings his total reported option holdings in this grant to 380,000 options, all held as direct ownership according to the filing.

What is the exercise price and term of the DMAC CEO’s new options?

The granted stock options have an exercise price of $5.84 per share and an expiration date of June 1, 2036. This means the CEO can buy DiaMedica Voting Common Shares at $5.84 any time before that expiration, subject to vesting.

How do the DiaMedica CEO’s options vest under this Form 4?

The options are scheduled to vest with 25% of the shares on the one-year anniversary of the grant date. The remaining 75% will vest in twelve equivalent quarterly installments, creating a multi-year vesting schedule tied to continued service.

Is the DiaMedica (DMAC) Form 4 a stock purchase or sale?

The Form 4 reports a grant, award, or other acquisition of derivative securities, coded as transaction type A. It is not an open-market buy or sell of common shares but an option award provided as part of compensation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/03/2026 - 05:23 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pauls Dietrich John

(Last) (First) (Middle)

301 CARLSON PARKWAY

SUITE 210

(Street)

MINNEAPOLIS MINNESOTA 55305

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
DiaMedica Therapeutics Inc. [ DMAC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President & CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$5.84	06/01/2026		A		380,000		(1)	06/01/2036	Voting Common Shares	380,000	$0	380,000	D

Explanation of Responses:

1. Scheduled to vest with respect to 25% of the shares on the one-year anniversary of the grant date, with the remaining shares scheduled to vest in twelve equivalent quarterly installments.

	/s/ Joshua L. Colburn, attorney-in-fact	06/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)